Yachika Kapoor 1 , Ruchika Sharma 1 , Anoop Kumar 2,3 . Show Affiliations »
Abstract
BACKGROUND: The emergence of infectious diseases and its resistance to approved drugs is a global threat to human health. The incidence of infectious diseases is increasing day by day and expected to rise exponentially in next 2 decades. Thus, there is a need for new treatment modalities for the treatment of microbial infections. METHODS: Thus, in the current investigation, we have explored the existing drugs [metformin (Anti-diabetic), propranolol (Anti-hypertensive) and amitriptyline (antidepressant)] for treatment of infectious diseases. RESULTS: An in-silico result of current investigation has shown the good interaction of metformin, propranolol, and amitriptyline towards various targets (Beta-lactamase, Penicillin-binding proteins, Staphylokinase protein, Oxidoreductase protein, etc.) of gram positive and gram negative bacteria as that of internal ligand. Further, in-vitro results have shown that the antibacterial activity of metformin, propranolol, and amitriptyline against Bacillus pumilus, Pseudomonas aeruginosa and Staphylococcus aureus. CONCLUSION: The parameters such as Microtiter assay: percentage growth retardation and bacterial growth kinetics, Minimum inhibitory concentration (MIC), Post-antibiotic assay and Biofilm formation have indicated the antibacterial potential of metformin, propranolol, and amitriptyline. However, before starting a clinical trial, complete safety and efficacy profile of drugs in the treatment of infectious diseases should be investigated. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
BACKGROUND: The emergence of infectious diseases and its resistance to approved drugs is a global threat to human health. The incidence of infectious diseases is increasing day by day and expected to rise exponentially in next 2 decades. Thus, there is a need for new treatment modalities for the treatment of microbial infections . METHODS: Thus, in the current investigation, we have explored the existing drugs [metformin (Anti-diabetic ), propranolol (Anti-hypertensive ) and amitriptyline (antidepressant)] for treatment of infectious diseases . RESULTS: An in-silico result of current investigation has shown the good interaction of metformin , propranolol , and amitriptyline towards various targets (Beta-lactamase, Penicillin-binding proteins, Staphylokinase protein, Oxidoreductase protein, etc.) of gram positive and gram negative bacteria as that of internal ligand. Further, in-vitro results have shown that the antibacterial activity of metformin , propranolol , and amitriptyline against Bacillus pumilus , Pseudomonas aeruginosa and Staphylococcus aureus . CONCLUSION: The parameters such as Microtiter assay: percentage growth retardation and bacterial growth kinetics, Minimum inhibitory concentration (MIC), Post-antibiotic assay and Biofilm formation have indicated the antibacterial potential of metformin , propranolol , and amitriptyline . However, before starting a clinical trial, complete safety and efficacy profile of drugs in the treatment of infectious diseases should be investigated. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Entities: Chemical
Disease
Gene
Species
Keywords:
In silico; In vitro studies; Infectious diseases; bacterial infections; drug repurposition; metformin; propranolol.
Mesh: See more »
Substances: See more »
Year: 2020
PMID: 30474540 DOI: 10.2174/1871526519666181126094244
Source DB: PubMed Journal: Infect Disord Drug Targets ISSN: 1871-5265